Piper Sandler analyst Allison Bratzel maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

BTIG Research has recently resumed Akebia Therapeutics Inc (AKBA) stock to Buy rating, as announced on November 29, 2023, according to Finviz. Earlier, on August 28, 2023, H.C. Wainwright had raised ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

Akebia (NASDAQ:AKBA) is scheduled to announce Q3 earnings results on Thursday, November 7th, before market open. The ...

Akebia Therapeutics ( (AKBA) ) has released its Q3 earnings. Here is a breakdown of the information Akebia Therapeutics presented to its ...

BTIG Research has recently resumed Akebia Therapeutics Inc (AKBA) stock to Buy rating, as announced on November 29, 2023, according to Finviz. Earlier, on August 28, 2023, H.C. Wainwright had raised ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. These figures ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $20 million in its third quarter. The Cambridge, Massachusetts-based company said ...

Butler, Chief Executive Officer of Akebia. "We expect to enter into contracts with additional dialysis providers to increase coverage over the remainder of 2024 while continuing our efforts to ...